PharmChem, Inc. Announces Exciting Acquisition
PharmChem, Inc. (PCHM), a prominent provider of innovative solutions for drug detection, has made headlines with its latest announcement regarding its acquisition by Alcohol Monitoring Systems, Inc. This strategic move is poised to enhance PharmChem’s offerings in the realm of compliance and public safety.
Details of the Acquisition Agreement
Under the terms of this new agreement, PharmChem shareholders are set to receive $3.75 per share in cash. This represents an impressive 22% premium over its recent closing price of $3.07. Such a valuation reflects the market's recognition of PharmChem's value and its strategic positioning within the industry.
Insight from the Board
Tim Eriksen, Chairman of the Board, expressed his positive outlook on this development. He noted that this successful acquisition validates the belief that PharmChem’s innovative products will thrive within a larger corporate framework, ultimately benefiting shareholders and customers alike.
Leadership Perspectives
Interim CEO Thompson Clark emphasized the rigor of the acquisition process, highlighting the multiple interested parties involved. He pointed out that joining forces with Alcohol Monitoring Systems will allow PharmChem to expand its reach and enhance service delivery to customers. "This acquisition represents a win for all stakeholders involved," Clark stated with optimism.
Alcohol Monitoring Systems’ Vision
Chris Linthwaite, CEO of Alcohol Monitoring Systems, also shared his excitement regarding the merger. He mentioned that the combination of PharmChem's drug testing capabilities with their existing alcohol and location monitoring technologies aligns perfectly with their mission of improving lives through compliance-based solutions. This synergy aims to address complex public safety needs.
Shareholder Approval and Future Steps
The transaction is contingent upon approval from PharmChem’s shareholders and satisfaction of customary closing conditions. The board has unanimously given the green light to this agreement, and PharmChem is currently working towards garnering the necessary support from 52% of outstanding shares. Additional information regarding the shareholder vote will be communicated shortly.
Contact Information for Inquiries
Shareholders or interested parties seeking further information about the acquisition are encouraged to reach out to the company’s CFO, Shana Veale, via email.
About PharmChem, Inc.
PharmChem, Inc. is renowned for being the sole manufacturer of the PharmChek Drugs of Abuse Sweat Patch. This innovative product has positioned PharmChem as a leader in drug detection technology.
Frequently Asked Questions
What is the purpose of the acquisition?
The acquisition aims to enhance PharmChem’s capabilities and expand its product offerings in drug detection technology.
How much will PharmChem shareholders receive?
Shareholders are set to receive $3.75 per share in cash following the acquisition.
What does the acquisition mean for PharmChem products?
Joining Alcohol Monitoring Systems will allow PharmChem to extend the reach of its products and services, ultimately benefiting customers and stakeholders.
When is the acquisition expected to close?
The acquisition is anticipated to close before the end of the third quarter, pending shareholder approval.
Who can I contact for more information?
For inquiries about the acquisition, shareholders can email CFO Shana Veale for further details.
